Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Goserelin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Proof of concept; Therapeutic Use
- 13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
- 07 Jun 2022 Results assessing the outcomes of 2 year-overall survival (2y-OS) and time-to-treatment failure (TTF) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 13 Oct 2021 Results published in the European Journal of Cancer